Could an arthritis drug help kids with duchenne MD? new trial aims to find out
NCT ID NCT06450639
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests satralizumab, a drug that calms inflammation, in 30 children aged 8 to 17 with Duchenne muscular dystrophy. The goal is to see if it improves bone density and muscle function. Participants receive injections for several months while continuing standard steroid therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
satralizumab (a drug that targets inflammation)
What this could lead to
If successful, this could point toward a new treatment to strengthen bones and slow muscle decline in children with Duchenne muscular dystrophy.
What could go wrong
This is an early Phase 2 study with only 30 participants, so results may not apply to all patients. The drug may not improve bone density or muscle function as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arkansas Children's Hospital
Little Rock, Arkansas, 72202, United States
-
Child's Hosp King's Daughters
Norfolk, Virginia, 23507, United States
-
Children's Healthcare of Atlanta Center for Advanced Pediatrics
Atlanta, Georgia, 30329, United States
-
Corewell Health
Grand Rapids, Michigan, 49503, United States
-
Fondazione IRCCS Istituto Neurologico ?Carlo Besta?
Milan, Lombardy, 20133, Italy
-
Hospital Sant Joan De Deu
Esplugues de Llobregas, Barcelona, 08950, Spain
-
Hospital U. Central de Asturias
Asturias, Principality of Asturias, 33011, Spain
-
Hospital Universitario Torrecardenas;Servicio de Neurologia
Almería, 04009, Spain
-
Hospital Universitario la Fe
Valencia, 46026, Spain
-
Instytut Centrum Zdrowia Matki Polki
Lodz, 93-338, Poland
-
Ivano-Frankivsk Regional Children Clinical Hospital
Ivano-Frankivsk, Kharkiv Governorate, 76018, Ukraine
-
Lvivska oblasna tsentralna likarnia
Lviv, 79010, Ukraine
-
Neurology Rare Disease Center
Flower Mound, Texas, 75028, United States
-
Ohmatdyt - National Specialized children's hospital of MoH of Ukraine
Kyiv, 01135, Ukraine
-
Policlinico Agostino Gemelli
Rome, Lazio, 00168, Italy
-
Rigshospitalet;Klinik for Børn og Unge med Hjerne- og Nervesygdomme
København Ø, 2100, Denmark
-
University of California Davis Medical Center
Sacramento, California, 95817, United States
-
Uniwersyteckie Centrum Kliniczne
Gdansk, 80-952, Poland
-
Uniwersyteckie Centrum Kliniczne WUM, Centralny Szpital Kliniczny
Warsaw, 02-097, Poland